申请人:Merck & Co., Inc.
公开号:US03932439A1
公开(公告)日:1976-01-13
Stabilized cycloserine compositions, having enhanced stability, and effective in releasing cycloserine compounds in vivo, are prepared by reacting D-4-amino-3-isoxazolidinone or its 5-methyl derivative with 2,4-pentanedione or alkyl-substituted-2,4-pentanedione to form the corresponding N-substituted-cycloserine compound in which one of the hydrogens attached to the primary amino group is replaced by 1-methyl-3-oxo-1-butenyl or an alkyl substituted-1-methyl-3-oxo-1-butenyl grouping. These D-4-(1'-methyl-3'-oxo-1'-butenyl or alkyl-substituted-1'-methyl-3'-oxo-1'-butenyl)amino-3-isoxazolidinones or 5-methyl derivative thereof, which may also be referred to as N-(1-methyl-3-oxo-1-butenyl or alkyl-substituted-1-methyl-3-oxo-1-butenyl)-derivative of cycloserine or methyl-cycloserine, as well as their pharmacologically acceptable salts, are remarkably stable on storage as well as upon oral administration, and are extremely effective in releasing in vivo the cycloserine compound containing the free primary amino grouping.
稳定的环丝氨酸组合物具有增强的稳定性,能够有效地在体内释放环丝氨酸化合物,通过将D-4-氨基-3-异噁唑烷酮或其5-甲基衍生物与2,4-戊二酮或烷基取代的2,4-戊二酮反应,形成相应的N-取代环丝氨酸化合物,其中连接到主要氨基团的氢原子之一被1-甲基-3-氧代-1-丁烯基或烷基取代的1-甲基-3-氧代-1-丁烯基取代。这些D-4-(1'-甲基-3'-氧代-1'-丁烯基或烷基取代的1'-甲基-3'-氧代-1'-丁烯基)氨基-3-异噁唑烷酮或其5-甲基衍生物,也可称为环丝氨酸的N-(1-甲基-3-氧代-1-丁烯基或烷基取代的1-甲基-3-氧代-1-丁烯基)衍生物或甲基环丝氨酸,以及它们的药理学可接受的盐,在储存时非常稳定,口服后也非常有效地在体内释放含有自由主要氨基团的环丝氨酸化合物。